Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 84Cisplatin 79Pemetrexed 72Docetaxel 62Drug Therapy 44Gemcitabine 43Erlotinib Hydrochloride 42Gefitinib 38Radiotherapy 36Paclitaxel 36pembrolizumab 31Bevacizumab 29icotinib 28osimertinib 27anlotinib 26Nivolumab 26camrelizumab 23Vinorelbine 23Radiosurgery 20aumolertinib 18atezolizumab 17sintilimab 16apatinib 16Endostatins 16endostar protein 15durvalumab 14Surgical Procedures, Operative 13Immunotherapy 13Immune Checkpoint Inhibitors 12Blood Specimen Collection 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Non-Small-Cell Lung × Trace amine-associated receptor 1 × Clear all
NCT02906150 2016-09-19

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

SciClone Pharmaceuticals

Phase 2 Unknown
140 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02906163 2016-09-19

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

SciClone Pharmaceuticals

Phase 1/2 Unknown
188 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡